Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2003;327:380-381 (16 August), doi:10.1136/bmj.327.7411.380
Regina Z Lilly, medical writer1
1 BMJ Unified, London WC1H 9JR rzlilly{at}netscape.net
The condition is characterised by the patient's inability to control the urge to indulge in binge eating. Medical complications are caused by the weight reducing behaviours, particularly vomiting and laxative misuse. The frequency of these behaviours is, on average, at least twice a week for three months. Episodes may be spontaneous or planned and can be triggered by stress, intense hunger, or dysphoria. Patients are usually in the normal weight range.
Treatments that are likely to work
Antidepressants
Antidepressants can reduce binge eating and purging, and improve depressive symptoms and attitude towards food. There is not enough evidence on how long the benefits last or for comparing the effects of different classes of antidepressants. Antidepressants and cognitive behaviour therapy are equally effective for bulimia nervosa, though dropout rates are higher with antidepressants, probably due to their side effects. For information on drug doses, see www.besttreatments.org/bulimianervosa.
Cognitive behaviour therapy
As with antidepressants, cognitive behaviour therapy can reduce binge eating and purging, and improve depressive symptoms and attitude towards food. It may be preferable to medication in patients who are sensitive to, or wish to avoid, side effects of medication. Cognitive behaviour therapy and other psychological treatments seem to be equally good at treating binge eating, although cognitive behaviour therapy is better at improving depression scores. There is some evidence that cognitive behaviour therapy has long term benefits in treating bulimia, but there is insufficient evidence about patients' characteristics that predict response.
Combination treatment with antidepressants and psychotherapy
Remission rates of some (but not all) symptoms are higher with combination treatment than with either treatment alone. Patients are more likely to withdraw from combined treatment or antidepressants alone than from psychotherapy alone. Some trials of combination treatment with antidepressants and psychotherapy have excluded patients with severe comorbid conditions such as depression and substance abuse, yet these conditions are common in patients seen in a clinical setting.
Other psychotherapies
Other psychotherapies, such as interpersonal psychotherapy and dialectical behaviour therapy (see definitions on www.besttreatments.org/bulimianervosa), are better than control (being on a waiting list for treatment) at improving binge eating and other symptoms of bulimia. The few trials of these psychotherapies have been hampered by small sample sizes and lack of blinding. It remains unclear which of these many techniques works best.
Treatments that need further study
Antidepressants as maintenance
There is not enough evidence on whether antidepressants have a role as maintenance therapy. Two very small randomised controlled trials (total of 18 patients) found that maintenance treatment with a tricyclic antidepressant was no better than placebo.
Newer antidepressants
There have been no randomised controlled trials of the newer antidepressants mirtazapine, reboxetine and venlafaxine in treating bulimia nervosa.
Selective serotonin reuptake inhibitors other than fluoxetine
The only selective serotonin reuptake inhibitor shown to work in bulimia nervosa is fluoxetine.
This extract is from www.besttreatments.org, a shared information resource for US patients and doctors that is based on Clinical Evidence (www.clinicalevidence.com). More information, including additional references for this BMJ article, is at www.besttreatments.org/bulimianervosa This extract will remain available on bmj.com. The rest of the BestTreatments website is currently available only to US doctors and patients who are members of United Healthcare Group health plans in the United States.
Competing interests: None declared.
What can you learn from this BMJ paper? Read Leanne Tite's Paper+